Generic Name and Formulations:
Sodium hyaluronate 20mg/2mL; soln for intra-articular inj.
Indications for HYALGAN:
Osteoarthritis of the knee in patients who have failed nonpharmacologic therapy and analgesics (eg, acetaminophen).
Prior to treatment: remove joint effusion (use separate syringe), if present; and give local anesthetic (eg, lidocaine) by SC inj. Inject 2mL intra-articularly in each affected knee weekly for 5 weeks. Use separate syringes for each knee.
Infection or skin disease at inj site.
Treatment cycle <3 injections: not recommended. Avian protein, feather, egg allergy. Avoid strenuous activity within 48hrs after injection. Pregnancy. Nursing mothers.
Avoid disinfectants with quaternary ammonium salts. Concomitant other intra-articular injectables: not recommended.
Inj site pain, local reactions, transient knee inflammation.
Single-use vials—1; Single-use prefilled syringes—1
Neurology Advisor Articles
- Excess Abdominal Obesity Linked to Severe Disability in Multiple Sclerosis
- Change in Dietary Patterns Over 5 Years in Early Multiple Sclerosis
- High-Dose Biotin May Be an Effective Treatment for Progressive MS
- Biobank Data Suggest Vitamin D Reduces Risk for Multiple Sclerosis
- Poor Functional Outcomes Tied to Depressive Symptoms in Multiple Sclerosis
- Managing Status Epilepticus in Palliative Care: Accounting for Patient and Family Experience
- Oxygen Desaturation Index Predicts AFib Risk in Ischemic Stroke
- Opioid Use Down With 'Enhanced Recovery After Surgery' Program
- Popular Heroin Inhalation Method Tied to Leukoencephalopathy
- Erenumab Superior to Placebo for Reducing Migraine Disability, Improving HRQoL